Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|September 14, 2020
Melflufen for relapsed and refractory multiple myelomaAlbert Oriol, Alessandra Larocca, Xavier Leleu, et al.
Leukemia & Lymphoma|January 14, 2016
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantationHeather Landau, Kevin Wood, David J Chung, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|November 8, 2017
Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell TransplantationShawn C Pun, Heather J Landau, Elyn R Riedel, et al.
JACC. Cardiooncology|October 29, 2020
Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL AmyloidosisKatherine Lee Chuy, Esther Drill, Ji Can Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinomaDarren R Feldman, Michael S Baum, Michelle S Ginsberg, et al.
Blood|June 26, 2014
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myelomaNikoletta Lendvai, Patrick Hilden, Sean Devlin, et al.
British Journal of Haematology|August 16, 2021
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxisKatrina Piedra, Tim Peterson, Carlyn Tan, et al.
British Journal of Haematology|February 7, 2020
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myelomaMarion Eveillard, Even Rustad, Mikhail Roshal, et al.
Leukemia & Lymphoma|August 10, 2011
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary diseaseHeather Landau, Neeta Pandit-Taskar, Hani Hassoun, et al.
Leukemia & Lymphoma|October 14, 2016
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiencyAdebayo Ogunniyi, Mabel Rodriguez, Sean Devlin, et al.
Pageof 8